Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

NCT05557838 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

AstraZeneca